Inhibrx Inc. is a clinical-stage biopharmaceutical company. It focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | $0.20M |
| Net Income (Most Recent Fiscal Year) | $1.69B |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 0.12 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.11 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 0.12 |
| Pre-Tax Margin (Trailing 12 Months) | 861486.44% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -85.12% |
| Return on Assets (Trailing 12 Months) | -58.90% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.12 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.12 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.04 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.52 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.80 |
| Earnings per Share (Most Recent Fiscal Year) | $112.62 |
| Diluted Earnings per Share (Trailing 12 Months) | $116.75 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 14.48M |
| Free Float | 12.00M |
| Market Capitalization | $199.04M |
| Average Volume (Last 20 Days) | 0.10M |
| Beta (Past 60 Months) | -- |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 17.09% |
| Percentage Held By Institutions (Latest 13F Reports) | 82.46% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |